Insights Into What’s New in Blood Cancer Care

December 8th 2025, 10:00pm

By Ryan Scott

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Epkinly Plus Chemo Elicits Durable Responses in DLBCL

December 8th 2025, 9:00pm

By Dr. Josh Brody

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

Zervyteg Shows Strong Responses in Acute Graft-Versus-Host Disease

December 8th 2025, 8:30pm

By Andrea Eleazar, MHS

Zervyteg improved responses and was safe in steroid- and Jakafi-resistant acute graft-versus-host disease affecting the GI tract in a phase 3 trial.

Updated Data Reinforce Treatment With Jaypirca in CLL/SLL

December 8th 2025, 3:54pm

By Jason Broderick

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Single-Drug Approach Explored for Newly Diagnosed Multiple Myeloma

December 8th 2025, 2:54pm

By Dr. Robert Orlowski

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

What I Want You to Know about Lynch Syndrome

December 8th 2025, 2:00pm

By Georgia Hurst

Jaypirca Matches Imbruvica's Effectiveness for CLL, With Hints of Long-Term Benefit

December 7th 2025, 7:58pm

By Jason M Broderick

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.

Epkinly Combo Effective in Second-Line R/R Follicular Lymphoma

December 7th 2025, 7:02pm

By Gina Mauro

The phase 3 EPCORE FL-1 trial showed that adding Epkinly to Rituxan and Revlimid delivered superior PFS and response rates.

A New Option Without Traditional Chemotherapy for Ph+ ALL

December 7th 2025, 6:49pm

By Ariana Pelosci

A new combination of Blincyto and Iclusig provided improved results and stronger responses for patients with Philadelphia chromosome-positive ALL compared with traditional chemotherapy.

Azacitidine Plus Venclexta Superior to Chemo in Acute AML

December 7th 2025, 5:47pm

By Jonah Feldman

Among fit patients with acute myeloid leukemia, azacitidine plus Venclexta was shown to be superior to intensive chemotherapy.

Older Patients With DLBCL May Benefit From First-Line Epkinly Plus R-mini-CHOP

December 7th 2025, 4:45pm

By Kristie L. Kahl

Among older patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), Epkinly plus R-mini-CHOP appeared to be well tolerated and elicited responses.

Higher Niktimvo Dosing Feasible in Chronic Graft-Versus-Host Disease

December 7th 2025, 3:19pm

By Kristie L. Kahl

Transitioning treatment with Niktimvo to a dose of 0.6 mg/kg every four weeks appeared feasible for chronic graft-versus-host disease.

Black Patients With AML Face Lower Survival Outcomes

December 7th 2025, 2:40pm

By Bridget Hoyt

Race has been identified as an independent prognostic factor in patients with AML receiving intensive chemotherapy.

KRd Improves Progression in Newly Diagnosed Patients With Myeloma

December 7th 2025, 12:35am

By Jax DiEugenio

KRd improved progression-free survival, deepened responses, and led to higher MRD negativity versus VRd in patients with newly diagnosed multiple myeloma.

Real-Time Text Tool Tracks Quality of Life in Myeloma Care

December 7th 2025, 12:05am

By Dr. James Berenson

Real-time text check-ins helped physicians identify issues sooner and support quality of life for patients with myeloma at ASH 2025.